<DOC>
	<DOCNO>NCT00691938</DOCNO>
	<brief_summary>This study design evaluate combination LBH589 decitabine patient age ≥ 60 year high risk Myelodysplastic Syndrome ( IPSS Int-2 High ) Acute Myeloid Leukemia .</brief_summary>
	<brief_title>LBH589 Plus Decitabine Myelodysplastic Syndromes ( MDS ) Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>To address need less toxic , effective treatment old patient advance MDS AML , purpose Phase 1-2 single institution study evaluate safety efficacy LBH 589 decitabine administer combination . Decitabine epigenetic modifier gene expression show well-tolerated population dose schedule propose study , reasonable efficacy . Although precise mechanism action incompletely understood , postulated work reactivate expression key tumor suppressor gene silence tumor cell reverse pattern hypermethylation promotor element . LBH389 likewise epigenetic modifier inhibits deacetylation histone non-histone protein , include HSP90 p53 . Although clinical experience LBH589 AML limit , aberrant histone deacetylase activity previously show play significant role pathogenesis AML . The addition LBH589 decitabine regimen previously establish efficacy tolerability allow u evaluate hypothesis two epigenetic modifier believe work distinct mechanism action may act together improve response patient treated decitabine alone , without significant additional toxicity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>AML ( except ( 15 ; 17 ) , inv ( 16 ) ( 8 ; 21 ) variant ) high risk MDS ( IPSS Int2 High ) diagnose accord WHO criterion ( see Appendix 1 ) Age ≥ 60 year old Not candidate allogeneic stem cell transplantation within next 12 week Ability provide write informed consent , obtain prior participation study relate procedure perform Patients must meet follow laboratory criterion : Serum albumin ≥ 3 g/dL Aspartate aminotransferase ( AST ) /SGOT alanine aminotransferase ( ALT ) /SGPT ≤ 2.5 x upper limit normal ( ULN ) ) ≤ 5.0 x ULN transaminase elevation due leukemic involvement Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min Serum potassium ≥ low limit normal ( LLN ) Serum phosphorus ≥ LLN Serum total calcium ( correct serum albumin ) serum ionized calcium ≥ LLN Serum magnesium ≥ LLN , thyroid stimulate hormone ( TSH ) free thyroxine ( T4 ) within normal limit ( WNL ) ( patient may thyroid hormone replacement ) Baseline MUGA ECHO must demonstrate leave ventricular ejection fraction ( LVEF ) ≥ low limit institutional normal . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Prior treatment MDS / AML Histone deacetylase ( HDAC ) inhibitor hypomethylating agent ( e.g. , Decitabine , azacitidine etc . ) Active central nervous system ( CNS ) involvement MDS/AML Impaired cardiac function include one following : Screening electrocardiogram ( ECG ) QTc &gt; 450 msec confirm central laboratory prior enrollment study Patients congenital long QT syndrome History sustain ventricular tachycardia Any history ventricular fibrillation torsades de pointes Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate ≥ 50 beat per minute eligible . Patients myocardial infarction unstable angina within 6 month study entry Congestive heart failure ( NY Heart Association class III IV ) Right bundle branch block leave anterior hemiblock ( bifasicular block ) Uncontrolled hypertension Concomitant use drug risk cause torsades de pointes Patients unresolved diarrhea &gt; CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Other concurrent severe and/or uncontrolled medical condition Patients receive chemotherapy investigational drug &lt; 2 week hydroxyurea &lt; 48 hour prior start study drug recover side effect therapy . Concomitant use anticancer therapy radiation therapy Male patient whose sexual partner woman child bear potential ( WOCBP ) use effective birth control Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen inability grant reliable informed consent Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapies Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LBH589</keyword>
	<keyword>Decitabine</keyword>
	<keyword>panobinostat</keyword>
	<keyword>histone deacetylase</keyword>
	<keyword>methylation</keyword>
	<keyword>hypomethylation</keyword>
</DOC>